ASCENTAGE PH.GRP SP.ADR/4
ASCENTAGE PH.GRP SP.ADR/4
Action · US04390B1052 · AAPG · A40ZYR (XNMS)
Aperçu Indicateurs financiers
27,54 EUR
6,29 % 1,63 EUR
Frankfurt (XNAS) · Cours et graphiques actuels sur MoneyPeak
12.06.2025 13:46

Cours actuels de ASCENTAGE PH.GRP SP.ADR/4

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
AAPG
USD
12.06.2025 13:46
31,62 USD
29,75 USD
+6,29 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
5,84 % 12,20 % 25,82 % 58,63 % 52,75 % 57,72 % 64,18 %

Profil de l'entreprise pour ASCENTAGE PH.GRP SP.ADR/4 Action

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Données de l'entreprise

Nom ASCENTAGE PH.GRP SP.ADR/4
Société Ascentage Pharma Group International
Symbole AAPG
Site web https://www.ascentage.cn
Marché d'origine XNMS Frankfurt
WKN A40ZYR
ISIN US04390B1052
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Dajun Yang M.D., Ph.D.
Capitalisation boursière 2 Mrd.
Pays Chine
Devise EUR
Employés 0,6 T
Adresse Suzhou Industrial Park, 215000 Suzhou
Date d'introduction en bourse 2025-01-24

Changements d'identifiant

Date De À
27.01.2025 AAPGV AAPG

Symboles boursiers

Nom Symbole
Frankfurt 36X0.F
NASDAQ AAPG

Autres actions

Les investisseurs qui détiennent ASCENTAGE PH.GRP SP.ADR/4 ont également les actions suivantes dans leur portefeuille :
GS F.C.INTL 24/26 MTN
GS F.C.INTL 24/26 MTN Obligation
MIZUHO FINL GRP 18/23
MIZUHO FINL GRP 18/23 Obligation
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025